靶向HER2阳性肿瘤的PET/CT分子显像临床研究进展
DOI: 10.3971/j.issn.1000-8578.2019.18.1016
Keywords: HER2,PET/CT,分子显像,靶向,New Targets for Molecular Therapy of Biliary Malignant Tumors,Application of PSMA PET/CT Specific Molecular Imaging in Diagnosis of Non-prostate Cancer,Value of 18F-FDG PET/CT in Evaluating Chemotherapeutic Effect of Diffuse Large B Cell Lymphoma Patients with Different CD5 Expression,Progress on Comprehensive Treatment of Nasopharyngeal Cancer,New NGR-targeted shRNA-loaded Liposome Suppresses Glioma Growth,Progress of Molecular Imaging in Diagnosis of HER2 Positive Tumors,Targeting CCL2-CCR2 Signaling Axis in Cancer Therapy,Feedback Activation of STAT3 Confers Resistance of HER2-positive Breast Cancer Cells to Lapatinib,Influence of NRP-1 Monoclonal Antibody on Growth of Breast Cancer Xenografts in Nude Mouse,PET/CT Imaging Characteristics of Abdominal Fibroblastic/Myofibroblastic Tumors and Its Application Value,Progress of Single-domain Antibodies in Molecular Imaging of Tumors,Correlation Between 18F-FDG PET/CT SUVmax and Clinicopathological Features, Neoadjuvant Chemotherapy Response in Invasive Ductal Breast Carcinoma Patients,Research Progress on PI3K/AKT/mTOR Signaling Pathway in Burkitt Lymphoma,Recurrent and Metastatic Characteristics and Prognosis of Advanced HER2-positive Breast Cancer Patients with Different HR Status,Correlation Between Ki67 Expression and 18F-FDG PET/CT SUVmax in Patient with Diffuse Large B-cell Lymphoma and Their Application in Therapeutic Effect Evaluation
Abstract:
摘要 人类表皮生长因子受体2（HER2） 在多种肿瘤组织中均有不同程度表达，曲妥珠单抗，可明显提高HER2阳性乳腺癌、胃癌的总生存时间。目前对HER2过表达的检测方法主要是免疫组织化学染色和荧光原位杂交法 ，但这种有创性的检查不能作为肿瘤疗效评价的常规检查而多次进行。靶向HER2的PET/CT分子显像，有望实时、无创监测全身病灶的HER2表达情况。目前靶向HER2的PET/CT分子显像主要包括核素标记抗体显像、核素标记亲和体显像、核素标记抗体片段及纳米抗体显像。靶向HER2的PET/CT显像可用于监测全身病灶的HER2表达情况，监测HER2表达的异质性，可用于原发乳腺癌HER2阴性患者阳性转移灶的筛选，同时也可用于靶向治疗的疗效预测。长半衰期核素铜、锆（64Cu、89Zr）标记完整抗体可直接评估HER2结合Trastuzumab的情况，但其血液药代动力学较慢，血液清除率较慢，需较长时间点的显像，辐射剂量较高。短半衰期核素（68Ga）标记亲和体显像、抗体片段及纳米抗体显像，由于其分子量小，生物分布快，注射药物后可短时间内显像（1~4 h），增加了患者的便利性，可重复显像，亲合体由于与抗体结合位点不同，可用于靶向治疗显像，另外其辐射剂量较低，可能更适于临床应用
Full-Text
